
    
      This study will enroll subjects with PPHN who do not show an adequate response to inhaled
      nitric oxide with the hypothesis that the addition of intravenous (IV) Remodulin will reduce
      the rate of clinical worsening as compared to standard of care. Additionally, this study aims
      to evaluate the treatment effect of Remodulin and better understand the dosing and
      pharmacokinetics in the neonatal population.
    
  